These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 31803950)

  • 1. Cannabinoids and the Microbiota-Gut-Brain Axis: Emerging Effects of Cannabidiol and Potential Applications to Alcohol Use Disorders.
    Karoly HC; Mueller RL; Bidwell LC; Hutchison KE
    Alcohol Clin Exp Res; 2020 Feb; 44(2):340-353. PubMed ID: 31803950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome.
    Al-Ghezi ZZ; Busbee PB; Alghetaa H; Nagarkatti PS; Nagarkatti M
    Brain Behav Immun; 2019 Nov; 82():25-35. PubMed ID: 31356922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global research trends in microbiome-gut-brain axis during 2009-2018: a bibliometric and visualized study.
    Zyoud SH; Smale S; Waring WS; Sweileh WM; Al-Jabi SW
    BMC Gastroenterol; 2019 Aug; 19(1):158. PubMed ID: 31470803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabidiol as a candidate pharmacotherapy for sleep disturbance in alcohol use disorder.
    Gendy MNS; Frey BN; Van Ameringen M; Kuhathasan N; MacKillop J
    Alcohol Alcohol; 2023 Jul; 58(4):337-345. PubMed ID: 37139966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review.
    Turna J; Syan SK; Frey BN; Rush B; Costello MJ; Weiss M; MacKillop J
    Alcohol Clin Exp Res; 2019 Apr; 43(4):550-563. PubMed ID: 30698831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.
    Rosenberg EC; Patra PH; Whalley BJ
    Epilepsy Behav; 2017 May; 70(Pt B):319-327. PubMed ID: 28190698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders
.
    Di Marzo V
    Dialogues Clin Neurosci; 2020 Sep; 22(3):259-269. PubMed ID: 33162769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic strategies of small molecules in the microbiota-gut-brain axis for alcohol use disorder.
    Xie L; Rungratanawanich W; Yang Q; Tong G; Fu E; Lu S; Liu Y; Akbar M; Song BJ; Wang X
    Drug Discov Today; 2023 May; 28(5):103552. PubMed ID: 36907319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabinoids as Immune System Modulators: Cannabidiol Potential Therapeutic Approaches and Limitations.
    Aziz AI; Nguyen LC; Oumeslakht L; Bensussan A; Ben Mkaddem S
    Cannabis Cannabinoid Res; 2023 Apr; 8(2):254-269. PubMed ID: 36413346
    [No Abstract]   [Full Text] [Related]  

  • 10. Bibliometric Visualization Analysis of Microbiome-Gut-Brain Axis from 2004 to 2020.
    Wang H; Long T; You J; Li P; Xu Q
    Med Sci Monit; 2022 May; 28():e936037. PubMed ID: 35568968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle.
    Gonzalez-Cuevas G; Martin-Fardon R; Kerr TM; Stouffer DG; Parsons LH; Hammell DC; Banks SL; Stinchcomb AL; Weiss F
    Neuropsychopharmacology; 2018 Sep; 43(10):2036-2045. PubMed ID: 29686308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The microbiota-immune axis as a central mediator of gut-brain communication.
    Fung TC
    Neurobiol Dis; 2020 Mar; 136():104714. PubMed ID: 31846737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabinoids and the gut: new developments and emerging concepts.
    Izzo AA; Sharkey KA
    Pharmacol Ther; 2010 Apr; 126(1):21-38. PubMed ID: 20117132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Mechanism of Cannabichromene and Cannabidiol Alone Versus in Combination in the Alleviation of Arthritis-Related Inflammation.
    Grogan G; Stephens K; Chou J; Timko MP; Cottler P; DeGeorge BR
    Ann Plast Surg; 2023 Jun; 90(6S Suppl 4):S408-S415. PubMed ID: 37332213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabidiol Adverse Effects and Toxicity.
    Huestis MA; Solimini R; Pichini S; Pacifici R; Carlier J; Busardò FP
    Curr Neuropharmacol; 2019; 17(10):974-989. PubMed ID: 31161980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabidiol improves the cognitive function of SAMP8 AD model mice involving the microbiota-gut-brain axis.
    Ma BQ; Jia JX; Wang H; Li SJ; Yang ZJ; Wang XX; Yan XS
    J Toxicol Environ Health A; 2024 Jun; 87(11):471-479. PubMed ID: 38590254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia.
    Junior NCF; Dos-Santos-Pereira M; Guimarães FS; Del Bel E
    Neurotox Res; 2020 Jan; 37(1):12-29. PubMed ID: 31637586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabidiol and periodontal inflammatory disease: A critical assessment.
    Jirasek P; Jusku A; Simanek V; Frankova J; Storch J; Vacek J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 May; 166(2):155-160. PubMed ID: 35332345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocannabinoids--at the crossroads between the gut microbiota and host metabolism.
    Cani PD; Plovier H; Van Hul M; Geurts L; Delzenne NM; Druart C; Everard A
    Nat Rev Endocrinol; 2016 Mar; 12(3):133-43. PubMed ID: 26678807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of Astrocyte Activity by Cannabidiol, a Nonpsychoactive Cannabinoid.
    Kozela E; Juknat A; Vogel Z
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28788104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.